Immunohistochemistry Market by Product (Antibodies, Reagents, Equipment, Kits), Application (Diagnostics (Cancer, Infectious, Autoimmune Diseases), Research, Forensic), End User (Hospitals, Diagnostic labs, Academia) & Region - Global Forecast to 2026
Updated on : March 28, 2023
The global Immunohistochemistry market in terms of revenue was estimated to be worth $2.3 billion in 2021 and is poised to grow at a CAGR of 7.7% from 2021 to 2026.
The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases, technological advancements in IHC, and availability of reimbursements for IHC tests. However, the high degree of consolidation in the by the major market players is expected to restrain the growth of this market during the forecast period.
To know about the assumptions considered for the study, Request for Free Sample Report
Immunohistochemistry Market Dynamics
Drivers: The rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases
The increasing geriatric population in developed as well as developing regions will positively influence the growth of the IHC market. With the rapid growth in the geriatric population globally, the prevalence of age-associated diseases is expected to increase significantly. According to the OECD, the number of elderly people living in the US was ~54 million in 2019. Other developed economies around the world also have large and growing geriatric populations. With age, the risk of developing diseases increases proportionately. Thus, the growth in the geriatric population is expected to increase the prevalence of various diseases across the globe. This is considered a key factor driving the growth of the IHC market for diagnostic applications.
Opportunities: Increasing demand for personalized medicine
Personalized medicine for non-small-cell lung cancer patients has proven to be extremely effective, and its use is expected to increase in the future. Immunohistochemistry techniques support this approach to treatment decision-making by performing the most complete and accurate histological subtyping of tumors possible (supported by predictive immunohistochemistry and the assessment of relevant biomarkers). Moreover, the increased availability of immunohistochemistry assays that detect mutant proteins (e.g., BRAF V600E and IDH1 R132H) provides a helpful replacement and/or adjunct for molecular testing. These techniques are highly reproducible, entail reasonable technical and interpretation complexity, and are available at relatively lesser costs, making them valuable novel tools in modern cancer care. The development of multiplex and mutation-specific immunohistochemistry assays represents important innovations, which provide improved utility in the context of personalized medicine and targeted therapy.
Restraints: High degree of consolidation
The global market is consolidated at the top, with the top three companies—F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US)—commanding a share of ~70%-80% in 2020.
Patent expiry of antibodies is a major challenge in the global market. Some of the primary antibodies manufactured and marketed by F. Hoffmann-La Roche AG (Switzerland) and Merck (Germany) are nearing patent expiration. As a result, the overall revenue and profitability of these market players are decreasing. Moreover, industry players are facing challenges such as rising price pressure from governments across the globe and reduced R&D output. To overcome these challenges, large market players are acquiring smaller and mid-sized market players that have innovative patented products. This provides a large financial and distribution platform for these products to increase their coverage into new markets globally.
Challenges: Dearth of skilled professionals
The demand for pathology services has increased significantly for clinical applications due to the increasing prevalence of cancer. Histopathology technologies account for the majority of the tests performed on cancer patients. However, there is a dearth of trained staff in these laboratories. A large number of histopathologists have reached retirement age, and a small number of histopathologists are being trained. On the other hand, laboratories are under pressure to process an increasing number of specimens with limited staff.
Diagnostic applications segment accounted for the largest share of Immunohistochemistry market
Based on application, the market is segmented into diagnostic, research, and forensic applications. The Diagnostic application segment dominated this market in 2020 and is estimated to register the highest growth during the forecast period. The growth of this segment is majorly attributed to factors such as the advantages of IHC over traditionally used special enzyme staining techniques that identify only a limited number of proteins, enzymes, and tissue structures. Therefore, IHC has become a crucial technique and is widely used for medical research as well as clinical diagnostics.
The antibodies segment accounted for the largest share of Immunohistochemistry market
Based on product, the market is segmented into antibodies, reagents, equipment, and kits. In 2020, the antibodies segment accounted for the largest share of 45.5% of the IHC market. Antibodies and Kits segment are seen to be the leading segments with respect to growth rate during the forecast period as a result of rapid development in the field of immunohistochemistry which has subsequently boosted the research and development of various antibodies in the past decade. Furthermore, antibodies are important diagnostic and therapeutic agents in immunology. Rising demand for complete solutions from a single provider and the advantage of simplification of IHC process is fuelling the growth of Kits segment.
Hospitals & Diagnostic Laboratories segment accounted for the largest share of Immunohistochemistry market
Based on end user, the market is segmented into hospitals & diagnostic laboratories, academic & research institutes, and other end users. The hospitals & diagnostic laboratories segment accounted for the largest share (74.8%) of the IHC market in 2020. The increasing number of specialty diagnostic tests performed in hospital laboratories, the rising number of in-house diagnostic procedures in hospitals, and the increasing trend of establishing in-house diagnostic capabilities in hospitals to provide time-bound and affordable patient services are factors driving the growth of this market segment.
To know about the assumptions considered for the study, download the pdf brochure
North America was the largest regional market for immunohistochemistry market
Based on the region, the market is broadly segmented into North America, Europe, Asia-Pacific and Rest of the World. APAC is expected to register the fastest growth rate during the forecast period owing to several factors, including increasing disposable income, rising healthcare spending, growing demand for quality medical care, and increasing investments by pharmaceutical and biopharmaceutical companies. The rising prevalence of chronic ailments, rapidly increasing geriatric population, growing academic and government investments in diagnostic research, and the presence of many market players are the other major factors driving the growth of the market in APAC.
Key players operating in the global immunohistochemistry market are F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US).
Immunohistochemistry Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2021 |
$2.3 billion |
|
Estimated Value by 2026 |
$3.3 billion |
|
Growth Rate |
Poised to grow at a CAGR of 7.7 % |
|
Market Segmentation |
Product, Application, End- User and Region |
|
Market Driver |
The rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases |
|
Market Opportunity |
Increasing demand for personalized medicine |
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
This study categorizes the global immunohistochemistry market to forecast revenue and analyze trends in each of the following submarkets
By Product
-
Antibodies
- Primary antibodies
- Secondary antibodies
-
Reagents
- Histological Stains
- Blocking Sera and Reagents
- Chromogenic Substrates
- Fixation Reagents
- Organic Solvents
- Proteolytic Enzymes
- Diluents
- Other Reagents (antigen retrieval solutions, stabilizers, controls, and mounting solutions)
-
Equipment
- Slide-staining Systems
- Tissue Processing Systems
- Slide Scanners
- Other Equipment (automated cover slippers, visualization equipment, microtomes, paraffin dispensers, slide labelers, and tissue microarrays)
-
Kits
- IHC Kits for Human tissue
- IHC Kits for Animal tissue
By Application
-
Diagnostic applications
- Cancer
- Infectious diseases
- Autoimmune diseases
- Nephrological diseases
- Neurological diseases
- Other diseases (ophthalmic, cardiovascular, dermatological, and dental diseases)
-
Research applications
- Drug development and Testing
- Other research applications (stem cell research and developmental biology)
- Forensic applications
By End user
- Hospitals & Diagnostic Laboratories
- Academic & research Institutes
- Other end users (CROs, pharma & biopharma companies, and forensic laboratories)
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe (RoE)
-
Asia Pacific (APAC)
- Japan
- China
- India
- Rest of Asia Pacific (RoAPAC)
-
Rest of the World (RoW)
- Latin America
- Middle East and Africa
Recent Developments
- In August 2021, Roche received FDA approval for VENTANA MMR RxDx companion diagnostic test based on immunohistochemistry for solid tumors that are deficient in the MMR pathway. The test identifies patients eligible for GSK’s anti-PD1 immunotherapy, JEMPERLI.
- In August 2021, Agilent received a CE-IVD mark in Europe for its PD-L1 IHC 22C3 pharmDx assay for the identification of oesophageal cancer patients for treatment with KEYTRUDA.
Frequently Asked Questions (FAQs):
What is the projected market value of the global Immunohistochemistry Market?
The global market of Immunohistochemistry is projected to reach USD 3.3 billion.
What is the estimated growth rate (CAGR) of the global Immunohistochemistry Market for the next five years?
The global immunohistochemistry market has an estimated annual growth rate of 7.7% and had a revenue size of approximately $2.3 billion in 2021.
What are the major revenue pockets in the Immunohistochemistry Market currently?
APAC is expected to register the fastest growth rate during the forecast period owing to several factors, including increasing disposable income, rising healthcare spending, growing demand for quality medical care, and increasing investments by pharmaceutical and biopharmaceutical companies. The rising prevalence of chronic ailments, rapidly increasing geriatric population, growing academic and government investments in diagnostic research, and the presence of many market players are the other major factors driving the growth of the market in APAC.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 44)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
TABLE 1 IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 50)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: IHC MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 IHC MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS) 2020
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2020
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 6 IHC MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
FIGURE 7 IHC MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
2.4 DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.5.1 COVID-19 SPECIFIC ASSUMPTIONS
2.6 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 61)
FIGURE 9 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 10 GLOBAL MARKET SHARE, BY APPLICATION, 2020
FIGURE 11 GLOBAL MARKET, BY END USER, 2021−2026
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 64)
4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW
FIGURE 13 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: MARKET SHARE, BY END USER AND COUNTRY (2020)
FIGURE 14 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC IHC MARKET IN 2020
4.3 GLOBAL MARKET FOR ANTIBODIES, BY TYPE
FIGURE 15 PRIMARY ANTIBODIES SEGMENT TO LEAD IHC ANTIBODIES MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 66)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 16 IHC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 2 IHC MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases
TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2019–2050)
FIGURE 17 CANCER INCIDENCE, BY REGION AND TYPE OF CANCER, 2020
5.2.1.2 Technological advancements in IHC
5.2.1.3 Availability of reimbursements for IHC tests
TABLE 4 CPT CODES FOR IHC PROCEDURES
5.2.2 RESTRAINTS
5.2.2.1 High degree of consolidation
TABLE 5 MAJOR ACQUISITIONS IN THE MARKET, 2018–2021
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing demand for personalized medicine
5.2.3.2 Growing significance of companion diagnostics
5.2.3.3 Growth opportunities in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Dearth of skilled professionals
TABLE 6 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018
5.2.4.2 Product failures and recalls
5.3 RANGES/SCENARIO
FIGURE 18 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF IHC MARKET
5.4 IMPACT OF COVID-19 OUTBREAK ON IHC MARKET
FIGURE 19 IHC MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019-2021
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 20 REVENUE SHIFT & NEW POCKET FOR IHC PROVIDERS
5.6 PRICING ANALYSIS
TABLE 7 AVERAGE SELLING PRICE OF SOME IHC EQUIPMENT, REAGENTS, AND KITS (2020)
5.7 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS OF IHC MARKET: RAW MATERIAL AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE
5.8 ECOSYSTEM ANALYSIS
FIGURE 22 ECOSYSTEM ANALYSIS: IHC MARKET
TABLE 8 SUPPLY CHAIN ECOSYSTEM
5.9 TECHNOLOGY ANALYSIS
5.10 PATENT ANALYSIS
FIGURE 23 PATENT GRANTED FOR IHC IN LAST 10 YEARS
TABLE 9 INDICATIVE LIST OF PATENTS IN IHC MARKET
5.11 REGULATORY ANALYSIS
5.11.1 US
TABLE 10 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
FIGURE 24 US: REGULATORY PROCESS FOR IVD DEVICES
5.11.2 CANADA
FIGURE 25 CANADA: REGULATORY PROCESS FOR IVD DEVICES
5.11.3 EUROPE
TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES
FIGURE 26 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
5.11.4 JAPAN
FIGURE 27 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
TABLE 12 JAPAN: CLASSIFICATION OF IVD REAGENTS
TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.11.5 CHINA
TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.11.6 INDIA
FIGURE 28 INDIA: REGULATORY PROCESS FOR IVD DEVICES
5.11.7 BRAZIL
FIGURE 29 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
5.12 PORTER’S FIVE FORCES ANALYSIS
TABLE 15 IHC MARKET: PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 BARGAINING POWER OF SUPPLIERS
5.12.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
6 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT (Page No. - 94)
6.1 INTRODUCTION
TABLE 16 GLOBAL MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
6.2 ANTIBODIES
TABLE 17 GLOBAL MARKET FOR ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 18 NORTH AMERICA: MARKET FOR ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 19 EUROPE: MARKET FOR ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 20 APAC: MARKET FOR ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 21 ROW: MARKET FOR ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 22 GLOBAL MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
6.2.1 PRIMARY ANTIBODIES
6.2.1.1 Wide applications in diagnostics and research to support demand for primary antibodies
TABLE 23 IHC MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 24 NORTH AMERICA: MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 25 EUROPE: MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 26 APAC: MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 27 ROW: MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
6.2.2 SECONDARY ANTIBODIES
6.2.2.1 Signal amplification through conjugation and comparatively easy manufacturing to drive market for secondary antibodies
TABLE 28 IHC MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 29 NORTH AMERICA: MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 30 EUROPE: MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 31 APAC: MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 32 ROW: MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
6.3 REAGENTS
TABLE 33 IHC MARKET FOR REAGENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 34 NORTH AMERICA: MARKET FOR REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 35 EUROPE: MARKET FOR REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 36 APAC: MARKET FOR REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 37 ROW: MARKET FOR REAGENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 38 IHC MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
6.3.1 HISTOLOGICAL STAINS
6.3.1.1 Developments in concurrent detection of multiple antigenic sites within single tissue specimen and cancer disease progression studies to propel market growth
TABLE 39 IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY REGION, 2019–2026 (USD MILLION)
TABLE 40 NORTH AMERICA: MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 41 EUROPE: IHC MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 42 APAC: MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 43 ROW: MARKET FOR HISTOLOGICAL STAINS, BY REGION, 2019–2026 (USD MILLION)
6.3.2 BLOCKING SERA AND REAGENTS
6.3.2.1 Blocking sera and reagents prevent nonspecific binding and reduce background noise and potentially false-positive results
TABLE 44 IHC MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 45 NORTH AMERICA: MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 46 EUROPE: MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 47 APAC: IHC MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 48 ROW: MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.3 CHROMOGENIC SUBSTRATES
6.3.3.1 Chromogenic substrates segment to register highest growth during forecast period
TABLE 49 IHC MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2019–2026 (USD MILLION)
TABLE 50 NORTH AMERICA: MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 51 EUROPE: MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 52 APAC: MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 53 ROW: MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2019–2026 (USD MILLION)
6.3.4 FIXATION REAGENTS
6.3.4.1 North America is largest market for fixation reagents
TABLE 54 IHC MARKET FOR FIXATION REAGENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 55 NORTH AMERICA: MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 56 EUROPE: MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 57 APAC: IHC MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 ROW: MARKET FOR FIXATION REAGENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.5 DILUENTS
6.3.5.1 Diluents are used to prepare antibody solutions
TABLE 59 IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 60 NORTH AMERICA: MARKET FOR DILUENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 61 EUROPE: MARKET FOR DILUENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 62 APAC: MARKET FOR DILUENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 63 ROW: MARKET FOR DILUENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.6 ORGANIC SOLVENTS
6.3.6.1 Organic solvents prevent physical damage in specimens and improve clarity while visualizing tissue samples
TABLE 64 IHC MARKET FOR ORGANIC SOLVENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 65 NORTH AMERICA: MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 66 EUROPE: IHC MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 67 APAC: MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 68 ROW: MARKET FOR ORGANIC SOLVENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.7 PROTEOLYTIC ENZYMES
6.3.7.1 Proteolytic enzymes improve accessibility of target antibodies
TABLE 69 MARKET FOR PROTEOLYTIC ENZYMES, BY REGION, 2019–2026 (USD MILLION)
TABLE 70 NORTH AMERICA: MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 71 EUROPE: MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 72 APAC: IHC MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 73 ROW: MARKET FOR PROTEOLYTIC ENZYMES, BY REGION, 2019–2026 (USD MILLION)
6.3.8 OTHER REAGENTS
6.3.8.1 Other reagents include antigen retrieval solutions, stabilizers, controls, and mounting solutions
TABLE 74 IHC MARKET FOR OTHER REAGENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 75 NORTH AMERICA: MARKET FOR OTHER REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 76 EUROPE: MARKET FOR OTHER REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 77 APAC: IHC MARKET FOR OTHER REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 78 ROW: MARKET FOR OTHER REAGENTS, BY REGION, 2019–2026 (USD MILLION)
6.4 EQUIPMENT
TABLE 79 IHC MARKET FOR EQUIPMENT, BY REGION, 2019–2026 (USD MILLION)
TABLE 80 NORTH AMERICA: MARKET FOR EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 81 EUROPE: MARKET FOR EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 82 APAC: MARKET FOR EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 83 ROW: MARKET FOR EQUIPMENT, BY REGION, 2019–2026 (USD MILLION)
TABLE 84 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
6.4.1 SLIDE-STAINING SYSTEMS
6.4.1.1 Development of high throughput staining systems to drive market growth
TABLE 85 IHC MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
TABLE 86 NORTH AMERICA: MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 87 EUROPE: IHC MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 88 APAC: MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 89 ROW: MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.4.2 TISSUE PROCESSING SYSTEMS
6.4.2.1 Technological advancements and need for automation due to shortage of skilled workforce to drive market growth
TABLE 90 MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
TABLE 91 NORTH AMERICA: MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 92 EUROPE: MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 93 APAC: MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 94 ROW: MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.4.3 SLIDE SCANNERS
6.4.3.1 Development of advanced multiplexed IHC scanners to drive market growth
TABLE 95 MARKET FOR SLIDE SCANNERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 96 NORTH AMERICA: MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 97 EUROPE: MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 98 APAC: MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 99 ROW: MARKET FOR SLIDE SCANNERS, BY REGION, 2019–2026 (USD MILLION)
6.4.4 OTHER EQUIPMENT
TABLE 100 MARKET FOR OTHER EQUIPMENT, BY REGION, 2019–2026 (USD MILLION)
TABLE 101 NORTH AMERICA: MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 102 EUROPE: MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 103 APAC: MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 104 ROW: MARKET FOR OTHER EQUIPMENT, BY REGION, 2019–2026 (USD MILLION)
6.5 KITS
TABLE 105 MARKET FOR KITS, BY REGION, 2019–2026 (USD MILLION)
TABLE 106 NORTH AMERICA: MARKET FOR KITS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 107 EUROPE: MARKET FOR KITS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 108 APAC: MARKET FOR KITS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 109 ROW: MARKET FOR KITS, BY REGION, 2019–2026 (USD MILLION)
TABLE 110 MARKET FOR KITS, BY TYPE, 2019–2026 (USD MILLION)
6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS
6.5.1.1 Increasing focus on cancer research to fuel market growth
TABLE 111 MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2019–2026 (USD MILLION)
6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS
6.5.2.1 Increasing preclinical drug testing to drive market growth
TABLE 112 MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2019–2026 (USD MILLION)
7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION (Page No. - 136)
7.1 INTRODUCTION
TABLE 113 GLOBAL MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
7.2 DIAGNOSTIC APPLICATIONS
TABLE 114 GLOBAL MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 115 NORTH AMERICA: MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 116 EUROPE: MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 117 APAC: MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 118 ROW: MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 119 GLOBAL MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
7.2.1 CANCER
7.2.1.1 Growing use of IHC tests for cancer diagnostics to fuel market growth
TABLE 120 COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
TABLE 121 MARKET FOR CANCER, BY REGION, 2019–2026 (USD MILLION)
TABLE 122 NORTH AMERICA: MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 123 EUROPE: MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 124 APAC: MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 125 ROW: MARKET FOR CANCER, BY REGION, 2019–2026 (USD MILLION)
7.2.2 INFECTIOUS DISEASES
7.2.2.1 Growing prevalence of infectious diseases and rising awareness of early diagnosis to propel market growth
TABLE 126 COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
TABLE 127 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 128 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 129 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 130 APAC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 131 ROW: MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)
7.2.3 NEPHROLOGICAL DISEASES
7.2.3.1 Wide application of IHC in transplant rejection expected to support market growth
TABLE 132 MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 133 NORTH AMERICA: MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 134 EUROPE: MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 135 APAC: MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 136 ROW: MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2019–2026 (USD MILLION)
7.2.4 AUTOIMMUNE DISEASES
7.2.4.1 Availability of numerous primary antibodies and rapid processing of results makes IHC a favorable diagnostic approach
TABLE 137 MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 138 NORTH AMERICA: MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 139 EUROPE: MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 140 APAC: MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 141 ROW: MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2019–2026 (USD MILLION)
7.2.5 NEUROLOGICAL DISEASES
7.2.5.1 Increasing global burden of neurological diseases to propel market growth
TABLE 142 COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR CENTRAL NERVOUS SYSTEM
TABLE 143 MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 144 NORTH AMERICA: MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 145 EUROPE: MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 146 APAC: MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 147 ROW: MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2019–2026 (USD MILLION)
7.2.6 OTHER DISEASES
TABLE 148 MARKET FOR OTHER DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 149 NORTH AMERICA: MARKET FOR OTHER DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 150 EUROPE: MARKET FOR OTHER DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 151 APAC: MARKET FOR OTHER DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 152 ROW: MARKET FOR OTHER DISEASES, BY REGION, 2019–2026 (USD MILLION)
7.3 RESEARCH APPLICATIONS
TABLE 153 MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 154 NORTH AMERICA: MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 155 EUROPE: MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 156 APAC: MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 157 ROW: MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 158 MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
7.3.1 DRUG DEVELOPMENT & TESTING
7.3.1.1 Quantitative image analysis makes IHC techniques ideal for drug testing
TABLE 159 MARKET FOR DRUG DEVELOPMENT & TESTING, BY REGION, 2019–2026 (USD MILLION)
7.3.2 OTHER RESEARCH APPLICATIONS
TABLE 160 MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
7.4 FORENSIC APPLICATIONS
TABLE 161 MARKET FOR FORENSIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 162 NORTH AMERICA: MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 163 EUROPE: MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 164 APAC: MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 165 ROW: MARKET FOR FORENSIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER (Page No. - 161)
8.1 INTRODUCTION
TABLE 166 GLOBAL MARKET, BY END USER, 2019–2026 (USD MILLION)
8.2 HOSPITALS & DIAGNOSTIC LABORATORIES
8.2.1 INCREASING INCIDENCE OF CANCER AND INFECTIOUS DISEASES TO INCREASE TESTING VOLUME IN CLINICAL LABORATORIES
TABLE 167 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 168 NORTH AMERICA: MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 169 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 170 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 171 ROW: MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
8.3 ACADEMIC & RESEARCH INSTITUTES
8.3.1 INCREASING USE OF IHC TESTS FOR DRUG DEVELOPMENT AND DISEASES DIAGNOSIS TO SUPPORT MARKET GROWTH
TABLE 172 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
TABLE 173 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 174 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 175 APAC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 176 ROW: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
8.4 OTHER END USERS
TABLE 177 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 178 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 179 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 180 APAC: MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 181 ROW: MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)
9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION (Page No. - 169)
9.1 INTRODUCTION
FIGURE 30 IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 182 IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2019–2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 31 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT
TABLE 183 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 184 NORTH AMERICA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 185 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 186 NORTH AMERICA: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 187 NORTH AMERICA: MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 188 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 189 NORTH AMERICA: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 190 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2.1 US
9.2.1.1 US is largest country-level market for immunohistochemistry
TABLE 191 RECENT DEVELOPMENTS IN US IHC MARKET
TABLE 192 US: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 193 US: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 194 US: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 195 US: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 196 US: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 197 US: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 198 US: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Increasing cancer cases in Canada to propel market growth
TABLE 199 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 200 CANADA: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 201 CANADA: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 202 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 203 CANADA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 204 CANADA: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 205 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3 EUROPE
TABLE 206 RECENT DEVELOPMENTS IN EUROPEAN IHC MARKET
TABLE 207 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 208 EUROPE: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 209 EUROPE: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 210 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 211 EUROPE: MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 212 EUROPE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 213 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 214 EUROPE: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Germany to dominate European IHC market
TABLE 215 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 216 GERMANY: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 217 GERMANY: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 218 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 219 GERMANY: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 220 GERMANY: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 221 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.2 FRANCE
9.3.2.1 Increasing use of IHC in cancer diagnosis and research to drive market growth
TABLE 222 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 223 FRANCE: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 224 FRANCE: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 225 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 226 FRANCE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 227 FRANCE: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 228 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.3 UK
9.3.3.1 Increasing number of cancer research studies to support market growth
TABLE 229 UK: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 230 UK: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 231 UK: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 232 UK: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 233 UK: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 234 UK: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 235 UK: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.4 ITALY
9.3.4.1 High incidence of cancer and rising geriatric population to support market growth in Italy
TABLE 236 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 237 ITALY: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 238 ITALY: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 239 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 240 ITALY: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 241 ITALY: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 242 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Increasing demand for personalized medicine will drive demand for IHC tests to find potential biomarkers
TABLE 243 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 244 SPAIN: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 245 SPAIN: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 246 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 247 SPAIN: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 248 SPAIN: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 249 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 250 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 251 ROE: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 252 ROE: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 253 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 254 ROE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 255 ROE: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 256 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 32 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT
TABLE 257 RECENT DEVELOPMENTS IN ASIA PACIFIC IHC MARKET
TABLE 258 ASIA PACIFIC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 259 ASIA PACIFIC: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 260 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 261 ASIA PACIFIC: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 262 ASIA PACIFIC: MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 263 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 264 ASIA PACIFIC: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 265 ASIA PACIFIC: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.1 JAPAN
9.4.1.1 Japan to dominate Asia Pacific immunohistochemistry market
TABLE 266 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 267 JAPAN: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 268 JAPAN: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 269 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 270 JAPAN: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 271 JAPAN: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 272 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.2 CHINA
9.4.2.1 China to register highest growth during forecast period
TABLE 273 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 274 CHINA: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 275 CHINA: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 276 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 277 CHINA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 278 CHINA: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 279 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 India is key destination for high-end pathology and diagnostic services
TABLE 280 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 281 INDIA: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 282 INDIA: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 283 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 284 INDIA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 285 INDIA: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 286 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 287 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 288 ROAPAC: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 289 ROAPAC: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 290 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 291 ROAPAC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 292 ROAPAC: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 293 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5 REST OF THE WORLD
TABLE 294 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 295 ROW: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 296 ROW: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 297 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 298 ROW: MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 299 ROW: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 300 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 301 ROW: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.1 LATIN AMERICA
9.5.1.1 Increasing incidence of cancer in Latin America driving market growth
TABLE 302 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 303 LATAM: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 304 LATAM: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 305 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 306 LATAM: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 307 LATAM: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 308 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.2 MIDDLE EAST AND AFRICA
9.5.2.1 Government initiatives focused on boosting healthcare infrastructure development to drive market growth
TABLE 309 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 310 MEA: MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 311 MEA: MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 312 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 313 MEA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 314 MEA: MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
TABLE 315 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 226)
10.1 OVERVIEW
10.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
FIGURE 33 KEY PLAYERS STRATEGIES IN IMMUNOHISTOCHEMISTRY MARKET, 2019- 2021
10.3 MARKET SHARE ANALYSIS
FIGURE 34 IMMUNOHISTOCHEMISTRY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
10.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 35 TOP MARKET PLAYERS DOMINATED IMMUNOHISTOCHEMISTRY MARKET FOR PAST 5 YEARS
10.5 COMPANY EVALUATION QUADRANT
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE
10.5.4 EMERGING COMPANIES
FIGURE 36 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT, 2020
10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 37 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
10.7 COMPANY PRODUCT FOOTPRINT
TABLE 316 PRODUCT PORTFOLIO ANALYSIS: IMMUNOHISTOCHEMISTRY MARKET (2020)
10.8 COMPANY GEOGRAPHIC FOOTPRINT
TABLE 317 GEOGRAPHIC REVENUE MIX: IMMUNOHISTOCHEMISTRY MARKET (2020)
10.9 COMPETITIVE SCENARIO
10.9.1 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2019–MARCH 2021
10.9.2 IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2019–MARCH 2021
10.9.3 IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS, JANUARY 2019–MARCH 2021
11 COMPANY PROFILES (Page No. - 240)
11.1 KEY COMPANIES
(Business overview, Products and Services offered, Recent developments, MNM view)*
11.1.1 F. HOFFMANN-LA ROCHE AG
TABLE 318 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
FIGURE 38 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)
11.1.2 DANAHER CORPORATION
TABLE 319 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
11.1.3 AGILENT TECHNOLOGIES, INC.
TABLE 320 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
11.1.4 MERCK KGAA
TABLE 321 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT (2020)
11.1.5 BIO-RAD LABORATORIES, INC.
TABLE 322 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 42 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
11.1.6 BIO-TECHNE CORPORATION
TABLE 323 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
FIGURE 43 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2020)
11.1.7 ABCAM PLC
TABLE 324 ABCAM PLC: BUSINESS OVERVIEW
FIGURE 44 ABCAM PLC: COMPANY SNAPSHOT (2020)
11.1.8 BECTON, DICKINSON AND COMPANY
TABLE 325 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
11.1.9 PERKINELMER, INC.
TABLE 326 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 46 PERKINELMER, INC.: COMPANY SNAPSHOT (2020)
11.1.10 TAKARA BIO, INC.
TABLE 327 TAKARA BIO, INC.: BUSINESS OVERVIEW
FIGURE 47 TAKARA BIO, INC.: COMPANY SNAPSHOT (2020)
11.1.11 THERMO FISHER SCIENTIFIC, INC.
TABLE 328 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 48 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
11.1.12 PHC HOLDINGS CORPORATION
TABLE 329 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW
11.1.13 CELL SIGNALING TECHNOLOGY, INC.
TABLE 330 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
11.1.14 BIO SB, INC.
TABLE 331 BIO SB, INC.: BUSINESS OVERVIEW
11.1.15 MILTENYI BIOTEC
TABLE 332 MILTENYI BIOTEC: BUSINESS OVERVIEW
11.1.16 CANDOR BIOSCIENCE GMBH
TABLE 333 CANDOR BIOSCIENCE GMBH: BUSINESS OVERVIEW
11.1.17 SAKURA FINETEK JAPAN CO., LTD.
TABLE 334 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 EAGLE BIOSCIENCES, INC.
TABLE 335 EAGLE BIOSCIENCES, INC.: COMPANY OVERVIEW
11.2.2 BIOCARE MEDICAL, LLC
TABLE 336 BIOCARE MEDICAL, LLC: COMPANY OVERVIEW
11.2.3 ELABSCIENCE, INC.
TABLE 337 ELABSCIENCE, INC.: COMPANY OVERVIEW
11.2.4 BIO-GENEX LABORATORIES
TABLE 338 BIO-GENEX LABORATORIES: COMPANY OVERVIEW
11.2.5 DIAGNOSTIC BIOSYSTEMS, INC.
TABLE 339 DIAGNOSTIC BIOSYSTEMS, INC.: COMPANY OVERVIEW
11.2.6 BIOVISION, INC.
TABLE 340 BIOVISION, INC.: COMPANY OVERVIEW
11.2.7 ROCKLAND IMMUNOCHEMICALS, INC.
TABLE 341 ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW
11.2.8 GENEMED BIOTECHNOLOGIES, INC.
TABLE 342 GENEMED BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW
*Business overview, Products and Services offered, Recent developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 346)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global immunohistochemistry market. Interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The market size was estimated through various secondary research approaches and triangulated with inputs from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources [such as the World Bank, World Health Organization (WHO), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Centre for Biotechnology Information (NCBI), Therapeutic Goods Administration (TGA), and Centers for Disease Control and Prevention (CDC)]; sites like ClinicalTrials.gov, fiercebiotech, and annual reports; SEC filings; press releases; investor presentations; journals; expert interviews; MarketsandMarkets analysis; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global market, which was validated through primary research.
Primary Research
After acquiring basic knowledge about the global market scenario through secondary research, extensive primary research was conducted. Several primary interviews were conducted with market experts from both the OEMs and supply and the demand side participants (such as clinical diagnostic laboratories, hospitals, etc. ) across four major regions—North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Immunohistochemistry Market Size Estimation
The global size of the market was estimated through different approaches. A detailed market estimation approach was followed to estimate and validate the global market value and other dependent submarkets, as mentioned below. Both top-down and bottom-up approaches were used to estimate and validate the total size of the biosimilars market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the immunohistochemistry business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, segment, and forecast the immunohistochemistry market based on product, application, end user, and region
- To provide detailed information about the factors influencing market growth, such as drivers, restraints, opportunities, and challenges
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
-
To forecast the size of the market segments with respect to four main regions, namely,
North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW) - To profile the key market players and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments, such as product launches, acquisitions, expansions, and partnerships, in the immunohistochemistry market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Geographic Analysis
- Further breakdown of the European immunohistochemistry market into countries from the Rest of Europe.
- Further breakdown of the Asia Pacific immunohistochemistry market into countries from the Rest of the APAC.
- Further breakdown of the Latin America immunohistochemistry market into Brazil, Mexico, and the Rest of Latin America.
Company Information
Detailed analysis and profiling of additional market players (up to 5), inclusive of:
- Business Overview
- Financial Information
- Product Portfolio
- Developments (Last Three Years)
Growth opportunities and latent adjacency in Immunohistochemistry Market
What are the growth estimates for the Global Immunohistochemistry Market by 2030?
Which geography holds the major share of the Global Immunohistochemistry Market?
Want to know more about growth strategies adopted by key players of the global Immunohistochemistry Market.